denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Research
Hematology Disease Topics & Pathways:
Research
Sunday, December 11, 2022: 11:15 AM-12:00 PM
Julia
(Marriott New Orleans Warehouse Arts District)
Panelists:
Helen E. Heslop, MD, DSc (Hon), Baylor College of Medicine
and
Thomas L. Ortel, MD, PhD, Duke University Medical Center
Disclosures:
Heslop: Tessa Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Fresh Wind Biotechnologies: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Millenium: Membership on an entity's Board of Directors or advisory committees; Ankarys: Membership on an entity's Board of Directors or advisory committees; Immunai: Membership on an entity's Board of Directors or advisory committees; Gilead Biosciences: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Kuur Therapeutics: Research Funding; Allovir: Current equity holder in publicly-traded company; Marker Therapeutics: Current equity holder in publicly-traded company; Kiadis: Divested equity in a private or publicly-traded company in the past 24 months.
See more of: Special-Interest Sessions